As result, the activation of these processes leads to a systemic low-grade inflammation with increased levels of cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-6, proposed as inflammatory markers of NAFLD (14). The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.